146 related articles for article (PubMed ID: 15446845)
1. Influenza virus neuraminidase inhibitors: generation and comparison of structure-based and common feature pharmacophore hypotheses and their application in virtual screening.
Steindl T; Langer T
J Chem Inf Comput Sci; 2004; 44(5):1849-56. PubMed ID: 15446845
[TBL] [Abstract][Full Text] [Related]
2. Binding interaction analysis of the active site and its inhibitors for neuraminidase (N1 subtype) of human influenza virus by the integration of molecular docking, FMO calculation and 3D-QSAR CoMFA modeling.
Zhang Q; Yang J; Liang K; Feng L; Li S; Wan J; Xu X; Yang G; Liu D; Yang S
J Chem Inf Model; 2008 Sep; 48(9):1802-12. PubMed ID: 18707092
[TBL] [Abstract][Full Text] [Related]
3. Virtual screening pipeline and ligand modelling for H5N1 neuraminidase.
D'Ursi P; Chiappori F; Merelli I; Cozzi P; Rovida E; Milanesi L
Biochem Biophys Res Commun; 2009 Jun; 383(4):445-9. PubMed ID: 19371724
[TBL] [Abstract][Full Text] [Related]
4. Neuraminidase pharmacophore model derived from diverse classes of inhibitors.
Zhang J; Yu K; Zhu W; Jiang H
Bioorg Med Chem Lett; 2006 Jun; 16(11):3009-14. PubMed ID: 16530411
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and structural analysis of inhibitors of influenza neuraminidase containing a 2,3-disubstituted tetrahydrofuran-5-carboxylic acid core.
Wang GT; Wang S; Gentles R; Sowin T; Maring CJ; Kempf DJ; Kati WM; Stoll V; Stewart KD; Laver G
Bioorg Med Chem Lett; 2005 Jan; 15(1):125-8. PubMed ID: 15582424
[TBL] [Abstract][Full Text] [Related]
6. Docking and 3D-QSAR studies of influenza neuraminidase inhibitors using three-dimensional holographic vector of atomic interaction field analysis.
Sun J; Cai S; Yan N; Mei H
Eur J Med Chem; 2010 Mar; 45(3):1008-14. PubMed ID: 19969399
[TBL] [Abstract][Full Text] [Related]
7. Human rhinovirus 3C protease: generation of pharmacophore models for peptidic and nonpeptidic inhibitors and their application in virtual screening.
Steindl T; Laggner C; Langer T
J Chem Inf Model; 2005; 45(3):716-24. PubMed ID: 15921461
[TBL] [Abstract][Full Text] [Related]
8. Fuzzy pharmacophore models from molecular alignments for correlation-vector-based virtual screening.
Renner S; Schneider G
J Med Chem; 2004 Sep; 47(19):4653-64. PubMed ID: 15341481
[TBL] [Abstract][Full Text] [Related]
9. Quantitative structure activity relationship studies on thiourea analogues as influenza virus neuraminidase inhibitors.
Nair PC; Sobhia ME
Eur J Med Chem; 2008 Feb; 43(2):293-9. PubMed ID: 17513019
[TBL] [Abstract][Full Text] [Related]
10. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors.
Abu Hammad AM; Taha MO
J Chem Inf Model; 2009 Apr; 49(4):978-96. PubMed ID: 19341295
[TBL] [Abstract][Full Text] [Related]
11. Pharmacophore identification, in silico screening, and virtual library design for inhibitors of the human factor Xa.
Krovat EM; Frühwirth KH; Langer T
J Chem Inf Model; 2005; 45(1):146-59. PubMed ID: 15667140
[TBL] [Abstract][Full Text] [Related]
12. A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models.
Gopalakrishnan B; Aparna V; Jeevan J; Ravi M; Desiraju GR
J Chem Inf Model; 2005; 45(4):1101-8. PubMed ID: 16045305
[TBL] [Abstract][Full Text] [Related]
13. Structure of a calcium-deficient form of influenza virus neuraminidase: implications for substrate binding.
Smith BJ; Huyton T; Joosten RP; McKimm-Breschkin JL; Zhang JG; Luo CS; Lou MZ; Labrou NE; Garrett TP
Acta Crystallogr D Biol Crystallogr; 2006 Sep; 62(Pt 9):947-52. PubMed ID: 16929094
[TBL] [Abstract][Full Text] [Related]
14. The discovery of new 11beta-hydroxysteroid dehydrogenase type 1 inhibitors by common feature pharmacophore modeling and virtual screening.
Schuster D; Maurer EM; Laggner C; Nashev LG; Wilckens T; Langer T; Odermatt A
J Med Chem; 2006 Jun; 49(12):3454-66. PubMed ID: 16759088
[TBL] [Abstract][Full Text] [Related]
15. Influence of the conditions in pharmacophore generation, scoring, and 3D database search for chemical feature-based pharmacophore models: one application study of ETA- and ETB-selective antagonists.
Cucarull-González JR; Laggner C; Langer T
J Chem Inf Model; 2006; 46(3):1439-55. PubMed ID: 16711764
[TBL] [Abstract][Full Text] [Related]
16. Strategies for generating less toxic P-selectin inhibitors: pharmacophore modeling, virtual screening and counter pharmacophore screening to remove toxic hits.
Ananthula RS; Ravikumar M; Pramod AB; Madala KK; Mahmood SK
J Mol Graph Model; 2008 Nov; 27(4):546-57. PubMed ID: 18993099
[TBL] [Abstract][Full Text] [Related]
17. Influenza virus neuraminidase: structure, antibodies, and inhibitors.
Colman PM
Protein Sci; 1994 Oct; 3(10):1687-96. PubMed ID: 7849585
[TBL] [Abstract][Full Text] [Related]
18. Pharmacophore modeling and in silico screening for new P450 19 (aromatase) inhibitors.
Schuster D; Laggner C; Steindl TM; Palusczak A; Hartmann RW; Langer T
J Chem Inf Model; 2006; 46(3):1301-11. PubMed ID: 16711749
[TBL] [Abstract][Full Text] [Related]
19. On the structure-based design of novel inhibitors of H5N1 influenza A virus neuraminidase (NA).
Mitrasinovic PM
Biophys Chem; 2009 Mar; 140(1-3):35-8. PubMed ID: 19117662
[TBL] [Abstract][Full Text] [Related]
20. Pharmacophore model of influenza neuraminidase inhibitors--a systematic review.
Gong JZ; Liu Y; Xu WF
Pharmazie; 2009 Oct; 64(10):627-32. PubMed ID: 19947162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
